New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
16:45 EDTANTH, LLYAnthera Pharmaceuticals acquires Sollpura from Eli Lilly
Anthera Pharmaceuticals (ANTH) announced that it has acquired Sollpura, a novel investigational Pancreatic Enzyme Replacement Therapy from Eli Lilly and Company (LLY). Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency, due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas. EPI is a major cause of serious nutritional deficiencies and long-term development issues, particularly in children with cystic fibrosis. EPI is estimated to afflict more than 150,000 patients in the United States alone, with more than US$600M spent on enzyme replacement therapy annually. Anthera intends to sublicense all rights, obligations, and intellectual property for the development and commercialization of Sollpura to Alkira Therapeutics. In the future, Alkira will secure appropriate funding as a wholly-owned subsidiary of Anthera to advance Sollpura into a phase 3 pivotal registration trial as agreed with the United States Food and Drug Administration in 2013. It is intended that Alkira will make all future contingent milestone payments under the license agreement upon product approval and on certain annual sales achievements and will make royalty payments on any product sales after achieving certain sales thresholds of cumulative net sales of Sollpura.
News For ANTH;LLY From The Last 14 Days
Check below for free stories on ANTH;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
06:10 EDTLLYEli Lilly downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Eli Lilly (LLY) to Neutral saying Alimta upside and the company's pipeline is largely priced into shares at current levels. Citi raised its price target for Lilly shares to $66 from $60 and said it prefers Bristol-Myers (BMY) and Pfizer (PFE) in the U.S.
July 29, 2014
08:50 EDTLLYHarris & Harris invests in Accelerator Corporation
Subscribe for More Information
July 28, 2014
17:51 EDTANTHAnthera Pharmaceuticals provides Q2 operational update
Subscribe for More Information
17:46 EDTANTHAnthera Pharmaceuticals reports Q2 EPS (34c), consensus (49c)
As of June 30, the company's cash, cash equivalents and restricted cash was $22.8M, compared to $35.9M at December 31, 2013.
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use